{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:10:23Z","timestamp":1790251823080,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Precise inter-laboratory quantitation of\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    RNA is critical for effective chronic myeloid leukemia (CML) disease management. Although standardized reporting on the International Scale (IS) was specifically developed to improve inter-laboratory reproducibility in\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    quantitation, the clinical impact of this reporting system has not been comprehensively assessed. We analyzed 15 years of\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    results (2009\u20132023) reported by over 200 clinical laboratories (6 annual samples; &gt;5500 results) in a College of American Pathologists proficiency testing program. Inter-laboratory precision was evaluated by standard deviations (SD) for high, intermediate, and low-transcript samples. Early rapid IS adoption over 7 years (8% of labs in 2009; 86% by 2015) was correlated with a progressive decrease in inter-lab SDs of reported\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    results (high-sample\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u2009\u22120.73,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004; intermediate-sample\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u2009\u22120.71,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.022; low-sample\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u2009\u22120.84,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002). IS implementation exceeded 99% by 2019, as inter-lab SD\u2019s reached their nadir value (~0.2). No other assessed variable correlated with time-dependent improvement in inter-lab reproducibility, including reference gene selection (\n                    <jats:italic>ABL1<\/jats:italic>\n                    versus others), RQ-PCR reagent selection, assay type (FDA-approved, commercial, or laboratory-developed), or practice setting. IS-based reporting is thus likely the principal driver of enhanced inter-laboratory precision in\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    quantitation, validating the real-world clinical relevance of adopting robust standardization in clinical molecular diagnostics.\n                  <\/jats:p>","DOI":"10.1038\/s41375-026-03062-6","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:50:44Z","timestamp":1785135044000},"page":"2236-2243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Improved inter-lab precision after CML international scale adoption: a 15-year history of BCR::ABL1 proficiency testing"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8699-2439","authenticated-orcid":false,"given":"Annette S.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek A.","family":"Oldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8669-7774","authenticated-orcid":false,"given":"Lawrence J.","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Vasalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-5144","authenticated-orcid":false,"given":"Richard D.","family":"Press","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"3062_CR1","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","volume":"99","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024;99:2191\u20132212.","journal-title":"Am J Hematol"},{"key":"3062_CR2","first-page":"1972","volume":"9","author":"JR Johnson","year":"2003","unstructured":"Johnson JR, Bross P, Cohen M, Rothmann M, Chen G, Zajicek A, et al. Approval summary: Imatinib mesylate capsules for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res. 2003;9:1972\u20139.","journal-title":"Clin Cancer Res"},{"key":"3062_CR3","unstructured":"Chronic myeloid leukemia. NCCN Guidelines Version 1. Plymouth Meeting: National Comprehensive Cancer Network; 2025."},{"key":"3062_CR4","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, et al. 2025 European Leukemianet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39:1797\u2013813.","journal-title":"Leukemia"},{"key":"3062_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jmoldx.2013.04.007","volume":"15","author":"RD Press","year":"2013","unstructured":"Press RD, Kamel-Reid S, Ang D. Bcr-abl1 rt-qpcr for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia. J Mol Diagn. 2013;15:565\u201376.","journal-title":"J Mol Diagn"},{"key":"3062_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28\u201337.","journal-title":"Blood"},{"key":"3062_CR7","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","volume":"112","author":"S Branford","year":"2008","unstructured":"Branford S, Fletcher L, Cross NC, M\u00fcller MC, Hochhaus A, Kim DW, et al. Desirable performance characteristics for bcr-abl measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112:3330\u20138.","journal-title":"Blood"},{"key":"3062_CR8","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","volume":"116","author":"HE White","year":"2010","unstructured":"White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y, et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood. 2010;116:e111\u2013e117.","journal-title":"Blood"},{"key":"3062_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2353\/jmoldx.2006.040404","volume":"8","author":"YL Wang","year":"2006","unstructured":"Wang YL, Lee JW, Cesarman E, Jin DK, Csernus B. Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of bcr-abl transcripts. J Mol Diagn. 2006;8:231\u20139.","journal-title":"J Mol Diagn"},{"key":"3062_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.5858\/arpa.2018-0336-CP","volume":"143","author":"JD Merker","year":"2019","unstructured":"Merker JD, Devereaux K, Iafrate AJ, Kamel-Reid S, Kim AS, Moncur JT, et al. Proficiency testing of standardized samples shows very high interlaboratory agreement for clinical next-generation sequencing-based oncology assays. Arch Pathol Lab Med. 2019;143:463\u201371.","journal-title":"Arch Pathol Lab Med"},{"key":"3062_CR11","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1001\/jamaoncol.2017.4021","volume":"4","author":"AS Kim","year":"2018","unstructured":"Kim AS, Bartley AN, Bridge JA, Kamel-Reid S, Lazar AJ, Lindeman NI, et al. Comparison of laboratory-developed tests and FDA-approved assays for BRAF, EGFR, and KRAS testing. JAMA Oncol. 2018;4:838\u201341.","journal-title":"JAMA Oncol"},{"key":"3062_CR12","doi-asserted-by":"publisher","first-page":"980","DOI":"10.5858\/arpa.2018-0394-CP","volume":"143","author":"LF Surrey","year":"2019","unstructured":"Surrey LF, Oakley FD, Merker JD, Long TA, Vasalos P, Moncur JT, et al. Next-generation sequencing (NGS) methods show superior or equivalent performance to Non-NGS methods on BRAF, EGFR, and KRAS proficiency testing samples. Arch Pathol Lab Med. 2019;143:980\u20134.","journal-title":"Arch Pathol Lab Med"},{"key":"3062_CR13","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.5858\/arpa.2018-0396-CP","volume":"143","author":"JT Moncur","year":"2019","unstructured":"Moncur JT, Bartley AN, Bridge JA, Kamel-Reid S, Lazar AJ, Lindeman NI, et al. Performance comparison of different analytic methods in proficiency testing for mutations in the BRAF, EGFR, and KRAS genes: a study of the College of American Pathologists Molecular Oncology Committee. Arch Pathol Lab Med. 2019;143:1203\u201311.","journal-title":"Arch Pathol Lab Med"},{"key":"3062_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1128\/JCM.01287-11","volume":"50","author":"RT Hayden","year":"2012","unstructured":"Hayden RT, Yan X, Wick MT, Xiong X, Ginocchio CC, Mitchell MJ, et al. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis. J Clin Microbiol. 2012;50:337\u201345.","journal-title":"J Clin Microbiol"},{"key":"3062_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.5858\/2007-131-185-DOCIGR","volume":"131","author":"MN Nikiforova","year":"2007","unstructured":"Nikiforova MN, Hsi ED, Braziel RM, Gulley ML, Leonard DG, Nowak JA, et al. Detection of clonal IGH gene rearrangements: summary of molecular oncology surveys of the College of American Pathologists. Arch Pathol Lab Med. 2007;131:185\u20139.","journal-title":"Arch Pathol Lab Med"},{"key":"3062_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.5858\/arpa.2019-0093-CP","volume":"144","author":"ES Keung","year":"2020","unstructured":"Keung ES, Souers RJ, Bridge JA, Faquin WC, Graham RP, Hameed MR, et al. Comparative performance of high-risk human papillomavirus RNA and DNA in situ hybridization on College of American Pathologists proficiency tests. Arch Pathol Lab Med. 2020;144:344\u20139.","journal-title":"Arch Pathol Lab Med"},{"key":"3062_CR17","first-page":"268","volume":"114","author":"HF Polesky","year":"1990","unstructured":"Polesky HF, Hanson MR. Human immunodeficiency virus type 1 proficiency testing. The American Association of Blood Banks\/College of American Pathologists program. Arch Pathol Lab Med. 1990;114:268\u201371.","journal-title":"Arch Pathol Lab Med"},{"key":"3062_CR18","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/bjh.14557","volume":"177","author":"S Scott","year":"2017","unstructured":"Scott S, Travis D, Whitby L, Bainbridge J, Cross NCP, Barnett D. Measurement of bcr-abl1 by rt-qpcr in chronic myeloid leukaemia: findings from an international EQA programme. Br J Haematol. 2017;177:414\u201322.","journal-title":"Br J Haematol"},{"key":"3062_CR19","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","volume":"17","author":"E Beillard","year":"2003","unstructured":"Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (rq-pcr)\u2014a Europe Against Cancer program. Leukemia. 2003;17:2474\u201386.","journal-title":"Leukemia"},{"key":"3062_CR20","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/s41375-022-01607-z","volume":"36","author":"HE White","year":"2022","unstructured":"White HE, Salmon M, Albano F, Andersen CSA, Balabanov S, Balatzenko G, et al. Standardization of molecular monitoring of CML: Results and recommendations from the European Treatment and Outcome Study. Leukemia. 2022;36:1834\u201342.","journal-title":"Leukemia"},{"key":"3062_CR21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.5858\/arpa.2013-0754-OA","volume":"139","author":"M Griffiths","year":"2015","unstructured":"Griffiths M, Patton SJ, Grossi A, Clark J, Paz MF, Labourier E. Conversion, correction, and international scale standardization: results from a multicenter external quality assessment study for bcr-abl1 testing. Arch Pathol Lab Med. 2015;139:522\u20139.","journal-title":"Arch Pathol Lab Med"},{"key":"3062_CR22","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1038\/leu.2016.90","volume":"30","author":"NC Cross","year":"2016","unstructured":"Cross NC, White HE, Ernst T, Dietz C, Saglio G, Mahon FX, et al. Development and evaluation of a secondary reference panel for bcr-abl1 quantification on the international scale. Leukemia. 2016;30:1844\u201352.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03062-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03062-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03062-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:43:28Z","timestamp":1790250208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03062-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3062"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03062-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8921143\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}